ERBB2 and breast carcinoma: To investigate the association between Bak and molecular subtypes of breast cancer, all of the 225 breast cancer cases were classified into the following groups: luminal (high Bak expression, n = 46; low Bak expression, n = 94) identified as ER+ and/or PR+, HER2 (high Bak expression, n = 28; low Bak expression, n = 37) identified as ER/PR- and HER2+, Basal-like (high Bak expression, n = 10; low Bak expression, n = 10) identified as ER/PR- and HER2- [13].